Related by context. All words. (Click for frequent words.) 72 Tesetaxel 72 Blinatumomab 71 sodium glucose cotransporter 71 Preclinical Data 71 Meets Primary Endpoint 70 Phase 2b Clinical Trial 70 Novel Mechanism 70 Epidermal Growth Factor Receptor 70 First Patient Dosed 70 Epratuzumab 70 Antitumor Activity 70 Tarvacin 70 Daclizumab 70 Anti Tumor Activity 70 AEG# 70 PEGylated Fab fragment 70 Monoclonal Antibody 69 Universal Flu Vaccine 69 pan HDAC inhibitor 69 Ridaforolimus 69 Tezampanel 69 Elesclomol 69 NEUGENE 69 Sphingomab 69 Perifosine 69 Phase IIb Trial 69 Kinase Inhibitor 69 Sapacitabine 69 Voreloxin 69 Hsp# Inhibitor 69 Clinical Trial Results 68 Ofatumumab 68 Pralatrexate 68 Cethromycin 68 Traficet EN 68 Elotuzumab 68 oral prodrug 68 Drug Candidate 68 Preclinical Study 68 RNAi Therapeutic 68 Novel Antibiotic 68 Aliskiren 68 Pharmacokinetic Study 68 Aflibercept 68 Tumor Necrosis Factor 68 Omacetaxine 68 orally administered inhibitor 68 Archexin 68 Albuferon TM 68 Sym# 68 Factor Receptor 68 sunitinib Sutent ® 68 Thiovir 68 targeting CD# 68 Oral Fingolimod 68 Bortezomib 68 Investigational Treatment 68 Therapeutic Vaccine 68 Vaccine Candidate 67 Phase 2b Trial 67 Anti Tumor 67 Belimumab 67 Ceftaroline 67 oral proteasome inhibitor 67 Completes Patient Enrollment 67 Cyclooxygenase Inhibiting Nitric Oxide 67 Romidepsin 67 Phase 2a Trial 67 Initiate Phase III 67 Antiangiogenic 67 Advanced Renal Cell 67 humanized monoclonal antibody 67 CYT# potent vascular disrupting 67 Humanized Anti 67 Maribavir 67 Phase 2a Clinical Trial 67 Aurora Kinase 67 Demonstrates Potent 67 Dose Escalation 67 Valopicitabine 67 Randomized Phase 67 Antiviral Activity 67 Interferon Gamma 67 Metastatic Melanoma 67 Linaclotide 67 Methylnaltrexone 67 Otelixizumab 67 Relapsed Refractory 67 imatinib Gleevec ® 67 Antitumor 67 Multimeric 67 ALN TTR 67 Receptor Agonist 67 Golimumab 67 Novel Oral 67 dasatinib Sprycel ® 67 Vicriviroc 67 BAL# [001] 67 orally bioavailable 67 Systemic Delivery 67 OMP #M# 67 Tarvacin TM 67 alpha folate receptor 67 Glufosfamide 66 Protease Inhibitor 66 Trial Evaluating 66 Dapagliflozin 66 Peginterferon 66 proteasome inhibitor 66 JAK Inhibitor 66 polymerase inhibitor 66 Pivotal Phase 66 Carfilzomib 66 selective kinase inhibitor 66 Tyrosine Kinase Inhibitor 66 Cutaneous T 66 MKC# MT 66 Metastatic Colorectal Cancer 66 Vidofludimus 66 Initiate Phase 66 multi kinase inhibitor 66 Initiates Phase II 66 Talabostat 66 Advanced Melanoma 66 Combination REOLYSIN R 66 investigational humanized monoclonal antibody 66 Dendritic Cells 66 Pertuzumab 66 Apaziquone 66 PKC# 66 erlotinib Tarceva ® 66 EZN 66 RAS MAPK pathway 66 Chronic Hepatitis C 66 antibody MAb 66 Disease Progression 66 IMA# 66 TKB# 66 FOLOTYN ® 66 Zalypsis 66 Well Tolerated 66 Vaccine Adjuvant 66 Bafetinib 66 selective orally bioavailable 66 Prolongs Survival 66 CCX# 66 protein tyrosine phosphatase 1B 65 Infected Patients 65 Milatuzumab 65 Pivotal Phase III 65 Presents Preclinical Data 65 AKT inhibitor 65 monoclonal antibody MAb 65 Radezolid 65 Phase III Trials 65 agonistic human 65 Investigational Agent 65 Phase 2b Study 65 Initiates Enrollment 65 Nitazoxanide 65 Complicated Skin 65 Enzastaurin 65 Pemetrexed 65 Investigational Compound 65 Denufosol 65 recombinant subunit vaccine 65 Phase III Clinical Trial 65 Patient Enrollment 65 Safinamide 65 Seliciclib 65 NS#/#A protease 65 Phase III Trial 65 peptidic compound 65 EGFr 65 XL# anticancer compounds 65 humanized antibody 65 investigational oral inhibitor 65 Phase III Pivotal 65 proteasome inhibitors 65 OncoVEX GM CSF 65 Malignant Melanoma 65 nucleoside reverse transcriptase inhibitor 65 Aplidin R 65 Study Evaluating 65 HCV protease 65 JAK2 Inhibitor 65 Liposomal 65 CCR9 antagonist 65 Vitro Activity 65 Eculizumab 65 humanized anti 65 LymphoStat B belimumab 65 Completes Enrollment 65 Pharmacokinetics PK 65 immunotherapeutic agent 65 MT#/MEDI-# 65 nucleoside analog 65 MEK Inhibitor 65 Romiplostim 65 M2 subunit 65 Diabetic Neuropathic Pain 65 PEGylated anti 65 Imetelstat 65 IAP inhibitor 65 Cannabinor 65 TNF Tumor Necrosis Factor 65 IgG1 antibody 65 Treatment Naïve 65 Irinotecan 65 Anthracyclines 65 Melphalan 65 Chemokine Receptor 65 Elvitegravir 65 neuraminidase inhibitor 65 Bevacizumab 65 mertansine 65 huC# DM4 65 novel nucleoside analog 65 XL# XL# 65 Demonstrates Efficacy 65 ganetespib 65 investigational monoclonal antibody 65 YONDELIS 65 Pooled Analysis 65 specific lectin receptors 65 IAP inhibitors 65 HGS ETR1 65 Lymphocytic 65 Aptamer 65 anti EGFR antibody 65 Radioimmunotherapy 65 liposomal formulation 64 Ozarelix 64 peripherally acting 64 Imprime PGG 64 Ceflatonin R 64 XYOTAX TM 64 Boceprevir 64 5 HT6 receptor 64 Granulocyte Colony Stimulating Factor 64 CD# antibodies 64 Trastuzumab 64 Bosutinib 64 Previously Treated 64 Adjuvanted 64 Copegus ribavirin 64 HDAC Inhibitor 64 delivered RNAi therapeutic 64 Xanafide 64 Investigational Drug 64 DermaVir Patch 64 Palifosfamide 64 Darinaparsin 64 Human Monoclonal Antibody 64 Drug Resistant 64 docetaxel Taxotere ® 64 TLR9 agonist 64 Combination Treatment 64 Elagolix 64 oncolytic vaccine 64 Renal Cell Carcinoma 64 Phase #b/#a clinical 64 Chronic Myeloid Leukemia 64 Improved Survival 64 Receives Orphan Drug Designation 64 PNP inhibitor 64 CTAP# Capsules 64 Immune Responses 64 VEGF receptor 64 Janus kinase 64 Immunotherapeutic 64 CBLC# 64 Cetrorelix 64 Curaxin CBLC# 64 Nexavar ® 64 soluble tumor necrosis 64 Achieves Primary Endpoint 64 Monoclonal 64 Ustekinumab 64 protein kinase inhibitor 64 Deforolimus 64 Initiates Clinical 64 DURECT proprietary 64 MEK inhibitor 64 Receptor Antagonist 64 II Clinical Trial 64 Naive Patients 64 Virulizin ® 64 recombinant adeno associated 64 RNAi Therapeutics 64 Erlotinib 64 chimeric monoclonal antibody 64 RGB # 64 somatostatin analogue 64 Alfacell proprietary ribonuclease 64 receptor tyrosine kinase inhibitor 64 Dalbavancin 64 Peginterferon Alfa 2a 64 Treatment Experienced 64 CEQ# 64 Payload TAP technology 64 TG# [001] 64 Peginterferon Alfa 2b 64 Antibody Drug Conjugate 64 triggers apoptosis programmed 64 Monotherapy 64 AMN# [001] 64 accumulate preferentially 64 MAGE A3 ASCI 64 Trodusquemine MSI 64 sorafenib tablets 64 non nucleoside inhibitor 64 Respiratory Virus 64 Treatment Naive Patients 64 Anticancer Compound 64 PRTX 64 Preclinical Models 64 Rigel R# 64 dependent kinase inhibitor 64 drug pipeline TAFA# 64 Interferons 64 First Patient Treated 64 Dasatinib 64 MUC1 64 Pulmonary Arterial Hypertension 64 targeted radiotherapeutic 64 HQK 64 T#I [002] 64 vinca alkaloid 64 Prostate Cancer Vaccine 64 Immunogenicity 64 pralatrexate injection folate analogue 64 Therapeutic Antibody 64 GLYX 64 selective modulator 64 Antithrombin 64 Tipranavir 64 Topline Results 64 oral kinase inhibitor 64 BAL# [002] 64 histone deacetylase HDAC inhibitor 64 Pegylated Interferon 64 HCV Protease Inhibitor 64 CYP#A# CYP#D# 64 Adjuvant Treatment 63 familial amyloidotic polyneuropathy FAP 63 Lung Cancer Drug 63 Vicinium TM 63 NS4A 63 EGFR TKI 63 HuMax HepC 63 Nasal Powder 63 HGS ETR1 mapatumumab 63 oral ghrelin agonist 63 immune modulatory 63 small molecule defensin 63 small molecule glucokinase 63 Preclinical Efficacy 63 Telaprevir VX 63 Entry Inhibitor 63 Previously Untreated 63 Thiarabine 63 Drug Shows Promise 63 NS5b 63 Colorectal Cancer Patients 63 Lupus Nephritis 63 Treatment Shows Promise 63 Adjuvant Chemotherapy 63 GW# [003] 63 Survival Benefit 63 virus HCV protease inhibitor 63 vascular disrupting agent 63 Present Preclinical Data 63 Dendritic Cell 63 Pafuramidine 63 Microplasmin 63 chemokine receptor 63 Epothilones 63 Oncolytic 63 Initiates Phase III 63 selective androgen receptor modulator 63 MKC# 63 AnaSpec Introduces 63 taxane derivative 63 rxRNA 63 MET amplification 63 radezolid 63 orally dosed 63 TRC# 63 Mouse Model 63 novel VDA molecule 63 Novel Therapeutic 63 Racivir 63 topical gel formulation 63 evaluating tivozanib 63 Nanobody 63 anti amnesic 63 hemorrhagic fever viruses 63 NXL# 63 MT# MEDI 63 BiTE ® 63 BRIM2 63 Ocrelizumab 63 Randomized Phase II 63 epothilones 63 Metastatic Prostate Cancer 63 MKC# MKC# PP 63 Is Well Tolerated 63 Small Molecule 63 HuMax EGFr 63 Lubiprostone 63 Chronic Hepatitis B 63 CD# CEA 63 Vandetanib 63 HSP# inhibitor 63 Cytotoxic T 63 2 methoxyestradiol 63 generation Hsp# inhibitor 63 Interferon Beta 63 humanized monoclonal 63 Hepatocellular Carcinoma 63 Hepatitis B Virus 63 Respiratory Syncytial Virus 63 generation nucleoside analog 63 Efficacy Trial 63 YONDELIS R 63 Anti Inflammatory Drug 63 ALN HPN 63 Molecular Diagnostic Test 63 DNA intercalator 63 anti phosphatidylserine 63 signal transduction inhibitors 63 Azedra 63 Phase IIb Clinical Trial 63 Successfully Completes Phase 63 Guanilib 63 CYC# 63 non peptidic protease 63 Interferon gamma 63 mapatumumab 63 JAK inhibitor 63 Metastatic Renal Cell Carcinoma 63 SAR# [002] 63 Clevudine 63 Bioral R 63 essential thrombocythemia ET 63 Patients Treated With 63 Gleevec resistant 63 anti CD# monoclonal 63 Pazopanib 63 TNF Blockers 63 SAR# [004] 63 CD# monoclonal antibody 63 CD4 monoclonal antibody 63 Gout Drug 63 Improves Survival 63 Pegylated 63 Breast Cancer Cells 63 Presents Positive 63 Alemtuzumab 63 Hormone Refractory Prostate Cancer 63 immunotoxin 63 ALN VSP 63 Novel Inhibitor 63 product candidate Lpathomab 63 Clinical Study Shows 63 DermaVir 63 Valortim R 63 rhIL 7 63 Randomized Double blind 63 CR# vcMMAE 63 Lenalidomide 63 Phase Ib IIa 63 HGS ETR2 63 BiTE R 63 antibody fragment 63 IgG1 monoclonal antibody 63 Antigen Specific 63 dasatinib Sprycel 63 Shows Promising 63 AAG geldanamycin analog 63 Tumour Vascular Disrupting Agent 63 HCV NS5B polymerase 63 antibody MT# 63 PSMA ADC 63 Obatoclax 63 Initiate Clinical Trial 63 Paclitaxel Carboplatin 63 Fulvestrant 63 BZL# 63 alpha 2a 63 Aurora kinase 63 RiVax 63 iobenguane 63 Vaccine Shows Promise 63 Factor VIIa 63 Brentuximab Vedotin SGN 63 Files IND 62 AMD# [003] 62 virosome 62 Onalta 62 ENMD # 62 metaglidasen 62 Mg Usa 62 OXi# 62 PEG SN# 62 Endothelial Cells 62 Transcription Factor 62 Naproxcinod 62 nucleoside analogue 62 Initiates Clinical Trial 62 novel topoisomerase 62 Experimental Vaccine 62 HuMax CD4 62 GVAX ® 62 Smac mimetics 62 Reovirus 62 Statistically Significant 62 Prostate Tumors 62 Polymerase Inhibitor 62 PROSTASCINT R 62 highly selective inhibitor 62 CCR5 antagonist 62 novel peptide 62 Inactivated 62 Initiates Phase 62 Aptivus ® 62 Ceflatonin 62 investigational antibody 62 bispecific 62 investigational immunotherapy 62 Tyrima 62 Alocrest 62 transcriptase inhibitors NNRTIs 62 IMiDs ® 62 signal transduction inhibitor 62 Enzyme Replacement Therapy 62 Pivotal Study 62 DAVANAT 62 GRN# 62 Develop Novel 62 drug conjugate 62 Dose Finding 62 nucleotide analogue 62 Onconase 62 evaluating picoplatin 62 VitiGam 62 ADCC enhanced 62 Mylan Receives Approval 62 Nilotinib 62 synthetic peptide 62 glioblastoma multiforme GBM 62 Zolinza 62 novel cardiac myosin 62 delafloxacin 62 Panzem R 62 Raltegravir 62 potent topoisomerase II 62 Pandemic Influenza Vaccine 62 PARP inhibitor 62 immunostimulatory 62 Severe Sepsis 62 Antigens 62 Vaccine Protects Against 62 Adenoviral 62 oncolytic virus therapies 62 Personalized Immunotherapy 62 Pimavanserin 62 5 HT4 62 Aviptadil 62 BAY #-# 62 Potent Antiviral Activity 62 Phase III Clinical Trials 62 Tumor Targeting 62 Potent Anti 62 PTP 1B 62 MVA BN R 62 Oral Anticoagulant 62 JVRS 62 Tumor Suppressor 62 GV# [001] 62 intravesical instillation 62 Recombinant Human 62 IRX 2 62 Palonosetron 62 ADP receptor antagonist 62 FDA Okays 62 OncoVEX 62 vinca alkaloids 62 Leukemias 62 Anticancer Activity 62 anti PlGF 62 tyrosine kinase inhibitor 62 Tesamorelin 62 Kahalalide F 62 metastatic colorectal 62 prophylactic vaccine 62 Shows Efficacy 62 Chronic Lymphocytic Leukemia 62 targeted antifolate 62 hypoxia inducible factor 62 novel oral tubulin 62 PEGylated 62 angiogenesis inhibitor 62 Tiotropium 62 Topical Treatment 62 R roscovitine CDK cyclin 62 Bezielle 62 Interferon alpha 62 HuCAL PLATINUM ® CysDisplay 62 brand ciclesonide HFA 62 Panzem R NCD 62 HCV polymerase inhibitors 62 Diabetic Nephropathy 62 potent inhibitor 62 Phase 1b Clinical Trial 62 Anticancer Agent 62 Angiolix 62 ribonucleotide reductase clinically validated 62 PEGylated interferon 62 Novel Small Molecule 62 Tofacitinib 62 Transdermal Patch 62 therapeutic monoclonal antibodies 62 OncoVex 62 Selective Inhibitor 62 ANG# 62 Treated Patients 62 IMPDH inhibitor 62 Mycophenolate Mofetil 62 Fluorouracil 62 Atripla combines 62 Unfractionated Heparin 62 siRNA therapeutic 62 preclinically 62 Bicifadine 62 Protein Kinase C 62 FOLFOX6 62 Inflammatory Disease 62 fosbretabulin 62 Cytotoxicity 62 Zoraxel 62 targeting miR 62 Pivotal Trial 62 Ceftobiprole 62 EndoTAG TM -1 62 recurrent metastatic ovarian cancer 62 HER2 Positive Breast Cancer 62 compound PMX # 62 HCV polymerase 62 ErbB2 positive 62 IMC A# 62 Olaparib 62 JAK1 62 NDA Submission 62 selective antagonist 62 anti angiogenic agent 62 R#/MEM # 62 Treatment Regimen 62 Biomarker Study 62 Hedgehog Pathway 62 FDA Accepts 62 A3 adenosine receptor 62 MTP inhibitor 62 IL# PE#QQR 62 metastatic hormone refractory 62 Calcitonin 62 Crizotinib 62 Sangamo BioSciences Announces 62 lead Aganocide compound 62 Shows Promise Against 62 Myeloma Patients 62 AVI BioPharma Announces 62 Gemcitabine 62 Milestone Payment 62 phosphatidylserine PS targeting 62 solithromycin 62 Initiates Dosing 62 BRAF inhibitor 62 RhuDex ® 62 conserved antigens NP 62 Pirfenidone 62 Liver Tumors 62 immunomodulator 62 docetaxel Taxotere R 62 Advanced Pancreatic Cancer 62 therapeutic monoclonal antibody 62 pertuzumab 61 Myelofibrosis 61 paclitaxel Taxol 61 Solazed ™ 61 Xenografts 61 Lupus Drug 61 Anti Angiogenesis 61 Inflammatory Diseases 61 Dose Ranging Study 61 Anthracycline 61 IND Filing 61 topically applied SEPA 61 world safest multivalent 61 Fibrinogen 61 HCV NS3 protease 61 OMP #R# 61 relapsed multiple myeloma 61 PDE# 61 Long Term Efficacy 61 HER2 receptor 61 Angiotensin 61 Copegus ® 61 Synthetic Peptide 61 Anticancer Drugs 61 Delafloxacin 61 Intravenous Human 61 attach auristatin 61 Cardiotoxicity 61 CDDO Im 61 Oral Calcitonin 61 Hematological Malignancies 61 Mipomersen 61 POTELLIGENT ® 61 Vidaza ® 61 oral dihydropyrimidine dehydrogenase DPD 61 Seasonal Allergic Rhinitis 61 Therapeutic Efficacy 61 Decitabine 61 Phase Ib II 61 Alinia 61 Tarvacin Anti Viral 61 systemic RNAi therapeutic 61 selective inhibition 61 KRN# 61 highly immunogenic 61 meropenem 61 Aganocide 61 DEB# 61 murine monoclonal antibody 61 Bucindolol 61 Immunogenic 61 TRAIL R2 61 Signaling Pathway 61 oral nucleoside analogue 61 Gastric Cancer 61 cytoprotective 61 Fast Track Status 61 ara C 61 Cholesterol Lowering Drug 61 Novel Compounds 61 humanised antibody 61 cancer vaccine Norelin 61 immunomodulating 61 fusion inhibitor 61 Therapeutic Vaccines 61 hypereosinophilic syndrome 61 LHRH antagonists 61 Antiviral Drugs 61 Orally Active 61 oral Janus kinase 61 proprietary polysaccharide 61 SinuNase TM 61 nilotinib Tasigna ® 61 Cell Lymphoma 61 Soluble CD# 61 Patients Suffering 61 peptide antigens 61 Disease Modifying 61 ALN PCS 61 Peginterferon alfa 2b 61 potent inhibition 61 generation URAT1 inhibitor 61 selective agonist 61 TRO# 61 MEK inhibitors 61 Kidney Transplant Patients 61 Pegasys ® 61 PDX pralatrexate 61 Newly Diagnosed 61 active cellular immunotherapies 61 RAV# 61 Hepatitis C Virus 61 Vitaxin 61 relapsed leukemia 61 Therapeutic Potential 61 Hepatocytes 61 Proxinium TM 61 cilengitide 61 Apixaban 61 alfa 2a 61 cetuximab Erbitux ® 61 Degarelix 61 EGFR HER2 61 OMNARIS HFA 61 HER3 61 Panitumumab 61 SGLT2 61 Fidaxomicin 61 Nicotine Vaccine 61 refractory chronic lymphocytic 61 VEGFR2 inhibitor 61 Ixabepilone 61 c MET 61 Virus Linked 61 Sirolimus Eluting 61 castrate resistant prostate cancer 61 Lenocta TM 61 PRT# 61 Solazed TM 61 Granted Orphan Drug 61 tenofovir disoproxil fumarate Viread 61 Study Showed 61 Mimetics 61 Seasonal Influenza Vaccine 61 bactericidal activity 61 MGd 61 vinorelbine tartrate 61 multitargeted 61 Relapsed Multiple Myeloma 61 IMC #B 61 hepatitis C HCV 61 AVP #D# 61 Gefitinib 61 B Cell Malignancies 61 Interferon Alpha 61 monoclonal antibody mAb 61 HCD# [002] 61 specific CCR9 antagonist 61 Telatinib 61 Second Pivotal Phase 61 Avian Flu Vaccine 61 Crofelemer 61 Prodrug 61 Diabetic Neuropathy 61 Bevirimat 61 Anthrax Toxin 61 Quinamed 61 Symadex 61 HuMax TAC 61 Intravenous CP 61 interleukin IL -# 61 Clinical Trial Evaluating 61 MEK ERK 61 Nimotuzumab 61 Dose Ranging 61 Platelet Derived Growth 61 antagomirs 61 Circulating Tumor Cells 61 favorable pharmacokinetic profile 61 von Willebrand Factor 61 DGAT1 inhibitors 61 Paraplatin ® 61 telomerase therapeutic 61 Exherin TM 61 Temsirolimus 61 BMS # 61 Gene Variation 61 Angiocept 61 Glatiramer Acetate 61 tubulin inhibitor 61 Efficacious 61 Oral Formulation 61 polymerase inhibitors 61 investigational pan BCR 61 thiazolides 61 anti CD3 61 PROCHYMAL 61 Novel Peptide 61 oral FTY# 61 Imatinib mesylate 61 immunomodulatory 61 Cethrin R 61 Saxagliptin 61 Slow Progression 61 Demonstrated Significant 61 Combo Therapy 61 Patients Receiving 61 Cancer Vaccines 61 Angiogenic 61 Single Dose 61 PSN# [002] 61 ISTODAX ® 61 Anti CD# Antibody 61 vidofludimus 61 Phase 1b clinical trials 61 JAK2 inhibitor 61 MYDICAR ® 61 INCB# [003] 61 Hepatitis C Patients 61 CCR2 61 vascular disrupting agents 61 cetuximab Erbitux R 61 Acute Ischemic Stroke 61 IMiDs R 61 Medullary Thyroid Cancer 61 Atiprimod 61 Hepatocellular 61 Antisense 61 Genes Predict 61 Refractory Hodgkin Lymphoma 61 #ME# 61 recurrent glioma 61 MCSP respectively 61 Vaccine Prevents 61 Castration Resistant Prostate Cancer 61 Submits NDA 61 unique alkylating agent 61 nucleotide analog 61 oral antiviral 61 ritonavir boosted 61 adalimumab Humira 61 Influenza Virus 61 Anti TNF 61 CA4P 61 CORT # 61 myelofibrosis polycythemia vera 61 Ecallantide 61 OHR/AVR# 61 Valortim TM 61 Multicenter Randomized 61 Kinase Inhibitors 61 Ebola Vaccine 61 Hepatitis B Vaccine 61 PDE4 inhibitor 61 MMAE 61 tumor vascular disrupting 61 Tamibarotene 61 Unresectable 61 relapsed MM 61 SCH # 61 Commences Phase 61 #D#C# 61 Integrase Inhibitor 61 Diffuse Large B 61 sphingosine 1 61 Pivotal Phase II 61 LY# [003] 61 HuMax CD# 61 Receptor Antagonists 61 ceftazidime 61 flavopiridol 61 attenuated strain 61 candidate deforolimus 61 Dengue Virus 61 Pivotal Trials 61 Novel Compound 61 Respiratory Syncytial Virus RSV 61 LHRH 61 K ras mutations 61 Combination Therapy 61 c Raf kinase 60 immunotherapeutics 60 ARRY # 60 Lacosamide 60 thymalfasin 60 Annamycin 60 potent antiproliferative 60 Kamada AAT 60 Imatinib 60 Thiazolidinediones 60 Pegloticase 60 chemically modified siRNA 60 intratumoral injection 60 Gastrointestinal Stromal Tumors 60 Completes Dosing 60 nanoviricides 60 Replacement Therapy 60 Chronic Lymphocytic Leukemia CLL 60 Inflammatory Arthritis 60 Pradefovir 60 amikacin 60 Cytomegalovirus 60 poly ADP ribose polymerase 60 Clofarabine 60 Curaxin 60 Gemzar ® 60 TG# [003] 60 Progenitor Cells 60 DG# compounds targeting 60 oral dual endothelin 60 Cloretazine ® 60 CRTH2 60 HuLuc# 60 Arimoclomol 60 Aplidin 60 Anticancer Drug 60 BiTE 60 Slows Progression 60 Regenerative Cells 60 SynCon ™ DNA 60 glycopeptide 60 Civacir 60 RNAi therapeutic targeting 60 Malaria Vaccine 60 Improves Outcomes 60 Provectus Pharmaceuticals specializes 60 Tolerability 60 renin inhibitor 60 Levofloxacin 60 Immunomedics Announces 60 Phase 2a Study 60 NY ESO